Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 11-14 |
| Number of pages | 4 |
| Journal | American Heart Journal |
| Volume | 243 |
| DOIs |
|
| Publication status | Published - 1 Jan 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American Heart Journal, Vol. 243, 01.01.2022, p. 11-14.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - A global perspective of racial differences and outcomes in patients presenting with acute heart failure
AU - Tromp, Jasper
AU - Ouwerkerk, Wouter
AU - Cleland, John G. F.
AU - Chandramouli, Chanchal
AU - Angermann, Christiane E.
AU - Dahlstrom, Ulf
AU - Ertl, Georg
AU - Hassanein, Mahmoud
AU - Perrone, Sergio V.
AU - Ghadanfar, Mathieu
AU - Schweizer, Anja
AU - Obergfell, Achim
AU - Dickstein, Kenneth
AU - Collins, Sean P.
AU - Filippatos, Gerasimos
AU - Lam, Carolyn S. P.
N1 - Funding Information: REPORT-HF: was funded by Novartis. C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore ; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma ; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd and Corpus; and serves as co-founder & non-executive director of Us2.ai. J.T has received personal grants and speaker fees from Olink proteomics and Roche diagnostics . GF reports research grants from the European Union . Committee fees from Novartis related to REPORT-HF. Committee member in trials and/or registries sponsored by Servier, BI, Medtronic, Vifor. CEA reports grants, personal fees and other from Novartis. She further acknowledges non-financial support from the University Hospital Würzburg , non-financial support from the Comprehensive Heart Failure Center Würzburg and grant support from the German Ministry for Education and Research (BMBF) . UD reports research support from Astra Zeneca, Pfizer, Boehringer Ingelheim, Vifor, Roche Diagnostics, Boston Scientific and speaker´s honoraria and consultancies from Astra Zeneca, Novartis and Amgen. MH received honoraria as a lecturer from Novartis, Aventis, Amgen, MSD, Astrazeneca and Merck. SPC reports research grants from NIH, AHRQ, AHA, PCORI and consulting fees from Novartis, Medtronic, Vixiar and Ortho Clinical. MG, AS and AO are employed by Novartis. JGFC reports grants and personal fees from Amgen, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from Bristol Myers Squibb, grants, personal fees and non-financial support from Medtronic, personal fees from Myokardia , grants, personal fees and non-financial support from Novartis , grants and personal fees from Philips, grants and non-financial support from Pharmacosmos , grants and non-financial support from PharmaNord , personal fees from Sanofi, personal fees from Servier, grants and personal fees from Stealth Biopharmaceuticals, grants and personal fees from Torrent Pharmaceuticals, grants, personal fees and non-financial support from Vifor , personal fees from Abbott. The remaining authors have nothing to disclose. Funding Information: REPORT-HF: was funded by Novartis. C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd and Corpus; and serves as co-founder & non-executive director of Us2.ai. J.T has received personal grants and speaker fees from Olink proteomics and Roche diagnostics. GF reports research grants from the European Union. Committee fees from Novartis related to REPORT-HF. Committee member in trials and/or registries sponsored by Servier, BI, Medtronic, Vifor. CEA reports grants, personal fees and other from Novartis. She further acknowledges non-financial support from the University Hospital Würzburg, non-financial support from the Comprehensive Heart Failure Center Würzburg and grant support from the German Ministry for Education and Research (BMBF). UD reports research support from Astra Zeneca, Pfizer, Boehringer Ingelheim, Vifor, Roche Diagnostics, Boston Scientific and speaker´s honoraria and consultancies from Astra Zeneca, Novartis and Amgen. MH received honoraria as a lecturer from Novartis, Aventis, Amgen, MSD, Astrazeneca and Merck. SPC reports research grants from NIH, AHRQ, AHA, PCORI and consulting fees from Novartis, Medtronic, Vixiar and Ortho Clinical. MG, AS and AO are employed by Novartis. JGFC reports grants and personal fees from Amgen, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from Bristol Myers Squibb, grants, personal fees and non-financial support from Medtronic, personal fees from Myokardia, grants, personal fees and non-financial support from Novartis, grants and personal fees from Philips, grants and non-financial support from Pharmacosmos, grants and non-financial support from PharmaNord, personal fees from Sanofi, personal fees from Servier, grants and personal fees from Stealth Biopharmaceuticals, grants and personal fees from Torrent Pharmaceuticals, grants, personal fees and non-financial support from Vifor, personal fees from Abbott. The remaining authors have nothing to disclose. Publisher Copyright: © 2021 Elsevier Inc.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Important racial differences in characteristics, treatment, and outcomes of patients with acute heart failure (AHF) have been described. The objective of this analysis of the International Registry to assess medical Practice with longitudinal observation for Treatment of Heart Failure (REPORT-HF) registry was to investigate racial differences in patients with AHF according to country income level.
AB - Important racial differences in characteristics, treatment, and outcomes of patients with acute heart failure (AHF) have been described. The objective of this analysis of the International Registry to assess medical Practice with longitudinal observation for Treatment of Heart Failure (REPORT-HF) registry was to investigate racial differences in patients with AHF according to country income level.
UR - http://www.scopus.com/inward/record.url?scp=85122488062&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ahj.2021.09.001
DO - https://doi.org/10.1016/j.ahj.2021.09.001
M3 - Comment/Letter to the editor
C2 - 34516969
SN - 0002-8703
VL - 243
SP - 11
EP - 14
JO - American Heart Journal
JF - American Heart Journal
ER -